This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



sonidegib (Odomzo®)


Reference No. 2617

Publication date:
10/12/2015


Appraisal information

sonidegib (Odomzo®) 200 mg hard capsule


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 09/12/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, sonidegib (Odomzo®) cannot be endorsed for use within NHS Wales for the treatment of adult patients with locally advanced basal cell carcinoma who are not amenable to curative surgery or radiation therapy.
Statement of Advice (SOA)
Download